Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer

Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer

Nivolumab is an immune checkpoint inhibitor with demonstrated efficacy against several malignant tumors. Alterations in driver oncogenes such as EGFR and ALK are a poor prognostic factor in nivolumab therapy for non-small cell lung cancer (NSCLC), whereas a smoking history is a well-known, favorable...

Full description

Bibliographic Details
Main Authors: Masahiro Yamasaki, Naomi Saito, Yu Hada, Sayaka Miyamoto, Hideharu Okanobu, Naoya Ikeda, Wakako Daido, Sayaka Ishiyama, Naoko Deguchi, Masaya Taniwaki, Nobuyuki Ohashi
Format: Article
Language:English
Published: Karger Publishers 2017-04-01
Series:Case Reports in Oncology
Subjects:
Nivolumab
Immune checkpoint inhibitor
Driver oncogene
ALK
Smoking
Multiple primary malignant tumors
Non-small cell lung cancer
Gastric cancer
Online Access:http://www.karger.com/Article/FullText/470830

Internet

http://www.karger.com/Article/FullText/470830

Similar Items